Cohort 4 of the Phase 1 atopic dermatitis trial evaluated soquelitinib over eight weeks and achieved 75% EASI75, 25% EASI90 and 33% IGA0/1 responses versus 20%, 0% and 0% for placebo. No severe or serious adverse events occurred in over 150 patients and no dose modifications were required in any trial.

Corvus completed a public offering that generated $189 million in net proceeds, extending its operating cash runway into the second quarter of 2028. This funding supports ongoing and planned clinical programs through key data readouts.

The company initiated a randomized, placebo-controlled Phase 2 atopic dermatitis trial enrolling approximately 200 patients across four dosing cohorts (200 mg QD, 200 mg BID, 400 mg QD and placebo) with a 12-week treatment and 90-day follow-up. Angel Pharmaceuticals is conducting a parallel Phase 1b/2 trial in China with 48 patients initially and up to 90 additional subjects planned, with initial results expected late this year.

Enrollment continues in the registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma involving 150 patients randomized to soquelitinib or physician’s choice chemotherapy, targeting progression-free survival with Orphan Drug and Fast Track designations. Corvus is also advancing an ALPS Phase 2 trial with NIAID, preparing Phase 2 studies in asthma and hidradenitis suppurativa, and developing next-generation ITK inhibitors in preclinical stages.